| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $5,594 | 4 | 31 |
Sells | $128,281 | 9 | 69 |
| Quinn William P. | President, CEO and CFO | 2 | $3,045 | 3 | $58,402 | $-55,357 |
| Nemec Sarah | Senior VP, Finance and PAO | 2 | $2,549 | 3 | $26,072 | $-23,524 |
| Yonehiro Grant | Chief Operating Officer | 0 | $0 | 3 | $43,807 | $-43,807 |
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low …
Over the last 12 months, insiders at Bolt Biotherapeutics, Inc. have bought $5,594 and sold $128,281 worth of Bolt Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Bolt Biotherapeutics, Inc. have bought $9,630 and sold $662,565 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Quinn William P. (President, CEO and CFO) — $3,045. Nemec Sarah (Senior VP, Finance and PAO) — $2,549.
The last purchase of 637 shares for transaction amount of $2,469 was made by Quinn William P. (President, CEO and CFO) on 2026‑06‑05.
| 2026-09-18 | Sale | Quinn William P. | President, CEO and CFO | 9,132 0.432% | $3.24 | $29,555 | +12.92% | |
| 2026-09-18 | Sale | Yonehiro Grant | Chief Operating Officer | 6,850 0.3241% | $3.24 | $22,169 | +12.92% | |
| 2026-09-18 | Sale | Nemec Sarah | Senior VP, Finance and PAO | 4,077 0.1929% | $3.24 | $13,195 | +12.92% | |
| 2026-09-17 | Sale | Quinn William P. | President, CEO and CFO | 6,545 0.3379% | $3.32 | $21,718 | +19.40% | |
| 2026-09-17 | Sale | Yonehiro Grant | Chief Operating Officer | 4,909 0.2534% | $3.32 | $16,290 | +19.40% | |
| 2026-09-17 | Sale | Nemec Sarah | Senior VP, Finance and PAO | 2,922 0.1508% | $3.32 | $9,696 | +19.40% | |
| 2026-09-16 | Sale | Quinn William P. | President, CEO and CFO | 1,889 0.1022% | $3.77 | $7,129 | +9.92% | |
| 2026-09-16 | Sale | Yonehiro Grant | Chief Operating Officer | 1,417 0.0767% | $3.77 | $5,348 | +9.92% | |
| 2026-09-16 | Sale | Nemec Sarah | Senior VP, Finance and PAO | 843 0.0456% | $3.77 | $3,181 | +9.92% | |
| 2026-06-05 | Quinn William P. | President, CEO and CFO | 637 0.0282% | $3.88 | $2,469 | -12.72% | ||
| 2026-06-05 | Nemec Sarah | Senior VP, Finance and PAO | 509 0.0225% | $3.88 | $1,973 | -12.72% | ||
| 2025-12-05 | Quinn William P. | President, CEO and CFO | 125 0.0055% | $4.61 | $576 | -16.33% | ||
| 2025-12-05 | Nemec Sarah | Senior VP, Finance and PAO | 125 0.0055% | $4.61 | $576 | -16.33% | ||
| 2024-12-16 | Quinn William P. | President, CEO and CFO | 2,500 0.0064% | $0.50 | $1,241 | -40.49% | ||
| 2024-12-16 | Nemec Sarah | Senior VP, Finance and PAO | 2,500 0.0064% | $0.50 | $1,241 | -40.49% | ||
| 2024-06-06 | Quinn William P. | President, CEO and CFO | 2,500 0.0065% | $0.64 | $1,594 | -23.93% | ||
| 2024-06-06 | Nemec Sarah | Senior VP, Finance and PAO | 2,500 0.0065% | $0.64 | $1,594 | -23.93% | ||
| 2023-12-12 | Quinn William P. | Chief Financial Officer | 7,500 0.0291% | $0.95 | $7,125 | -23.90% | ||
| 2023-12-06 | Quinn William P. | Chief Financial Officer | 2,500 0.008% | $0.78 | $1,955 | -17.55% | ||
| 2023-11-30 | Sale | ENGLEMAN EDGAR | director | 123,079 0.4308% | $0.86 | $105,614 | -10.79% |
| Quinn William P. | President, CEO and CFO | 25384 1.3177% | $166,772.88 | 11 | 3 | <0.0001% |
| Nemec Sarah | Senior VP, Finance and PAO | 17082 0.8868% | $112,228.74 | 4 | 3 | <0.0001% |
| Novo Holdings A/S | 3703991 192.2808% | $24.34M | 1 | 1 | <0.0001% | |
| HEALY JAMES | director | 2754437 142.9877% | $18.1M | 1 | 0 | <0.0001% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2754437 142.9877% | $18.1M | 1 | 0 | <0.0001% |
| ENGLEMAN EDGAR | director | 251522 13.057% | $1.65M | 1 | 7 | <0.0001% |
| Vivo Capital VIII, LLC | 10 percent owner | 111662 5.7966% | $733,619.34 | 1 | 5 | <0.0001% |
| Schatzman Randall C | Chief Executive Officer | 1500 0.0779% | $9,855.00 | 1 | 0 | <0.0001% |
| Perez Edith A. | Chief Medical Officer | 1328 0.0689% | $8,724.96 | 2 | 0 | <0.0001% |
| LAPORTE KATHLEEN | director | 1200 0.0623% | $7,884.00 | 1 | 0 | <0.0001% |
| Khanna Ashish Siri Ram | director | 1200 0.0623% | $7,884.00 | 1 | 0 | <0.0001% |
$18,815,063 | 62 | -6.45% | $13.7M | |
$1,993,425 | 46 | -21.91% | $13.95M | |
$95,567,744 | 39 | -17.01% | $10.94M | |
$30,257,839 | 29 | -15.72% | $12M | |
$76,600 | 22 | -38.58% | $10.49M |
| Increased Positions | 7 | +24.14% | 86,402 | +11.18% |
| Decreased Positions | 10 | -34.48% | 287,900 | -37.26% |
| New Positions | 3 | New | 58,756 | New |
| Sold Out Positions | 6 | Sold Out | 159,511 | Sold Out |
| Total Postitions | 26 | -10.34% | 571,233 | -26.08% |
| Vivo Capital, Llc | $1,019.00 | 8.8% | 176,064 | 0 | 0% | 2025-09-30 |
| Sofinnova Investments, Inc. | $797.00 | 6.89% | 137,721 | 0 | 0% | 2025-09-30 |
| Pivotal Bioventure Partners Investment Advisor Llc | $548.00 | 4.73% | 94,573 | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $387.00 | 3.34% | 66,879 | -100,000 | -59.92% | 2025-09-30 |
| Nan Fung Group Holdings Ltd | $338.00 | 2.92% | 58,347 | 0 | 0% | 2025-09-30 |
| Samsara Biocapital, Llc | $283.00 | 2.44% | 48,830 | -3,626 | -6.91% | 2025-09-30 |
| Board Of Trustees Of The Leland Stanford Junior University | $208.00 | 1.8% | 35,978 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $198.00 | 1.71% | 34,231 | -24,253 | -41.47% | 2025-09-30 |
| Renaissance Technologies Llc | $166.00 | 1.43% | 28,625 | +10,300 | +56.21% | 2025-09-30 |
| Geode Capital Management, Llc | $107.00 | 0.93% | 18,533 | 0 | 0% | 2025-09-30 |